Silibinin attenuates arsenic induced alterations in serum and hepatic lipid profiles in rats

Journal of Applied Pharmaceutical Science

Volumn 3, Issue 2, 2013, Pages 132-138

  Muthumani, M ^a   Milton Prabu, S ^a  

^a ANNAMALAI UNIVERSITY   (India)

Author keywords

Arsenic; Lipids; Liver; Rats.; Silibinin

Indexed keywords

EID: 84876014257     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2013.30223     Document Type: Article

References (43)

1. Akhand A.A., Du J., Liu W., Hossain K., Miyata T., Nagase F., Kato M., Suzuki H. and Nakashima I. Redox-Linked Cell Surface- Oriented Signaling for T-Cell Death. Antioxid. Redox Signal. 2002: 4: 445-454.
2. Basiglio C.L., Sanchez Pozzi E.J., Mottino A.D. and Roma M.G. Differential effects of silymarin and its active component SB on plasma membrane stability and hepatocellular lysis. Chemico. Biol. Interact. 2009: 179: 297-303.
3. Bode A.M. and Dong Z. The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit. Rev. Oncol. Hematol. 2002:42: 5-24.
4. Chattopadhyay S., Maiti S., Maji G., Deb B., Pan B. and Ghosh D. Protective Role of Moringa oleifera (Sajina) Seed on Arsenic-Induced Hepatocellular Degeneration in Female Albino Rats. Biol. Trace Elem. Res. 2011: 142: 200-212.
5. Chen C.J., Wang S.L., Chiou J.M., Tseng C.H., Chiou H.Y., Hsueh Y.M., Chen S.Y., Wu M.M and Lai M.S. Arsenic and diabetes and hypertension in human populations: a review. Toxicol Appl. Pharmacol. 2007:222: 298-304.
6. Chovaneikova M. and Simek V. Effects of high-fat and Chlorella vulgaris feeding on changes in lipid metabolism in mice. Biologia Bratislava 2001:56: 661-666.
7. Enas E.A. and Mehta J. Malignant coronary artery disease in young asian indians: Thoughts on pathogenesis, prevention, and therapy. Clin. Cardiol. 1995:18: 131-135.
8. Erlejman A.G., Verstraeten S.V., Fraga C.G. and Oteiza P.I. The interaction of flavonoids with membranes: potential determinant of flavonoid antioxidant effects. Free Radical Res. 2004:38: 1311-1320.
9. Ferenci P. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J. Hepatol., 1989: 9: 105-113.
10. Flora S.J.S., Mittal M. and Mehta A. Heavy metal induced oxidative stress and its possible reversal by chelation therapy. Indian J. Med. Res. 2008:128: 501-523.
11. Ford E.S., Giles W.H. and Dietz W.H. Prevalence of the metabolic syndrome among US adults. JAMA. 2002:287: 356-359.
12. Goldberg D.M. and Watts C. Serum enzyme changes as evidence of liver reaction of oral alcohol. Gastroenterology. 1965:49: 256-261.
13. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer H.B. Jr., Clark L.T. and Hunninghake D.B. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004:110: 227-239.
14. Hartwig A., Groblinghoff U.D., Beyersmann D., Natarajan A.T., Filon R. and Mullenders L.H. Interaction of arsenic (III) with nucleotide excision repair in UV-irradiated human fibroblasts. Carcinogenesis. 1997:18: 399-405.
15. Hossain K., Akhand A.A., Kato M., Du J., Takeda K., Wu J., Takeuchi K., Liu W., Suzuki H. and Nakashima I. Arsenite induces apoptosis of Murine T ymphocytes through membrane raft-linked signaling for activation of cJun amino-terminal kinase. J. Immunol. 2000:165: 4290-4297.
16. LaRosa J., Hunninghake D., Bush D., Criqui M.H., Getz G.S. and Gotto A.M.Jr. The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation. 1990:81: 1721-1733.
17. Liu D.N., Lu X.Z., Li B.L., Zhou D.X., Li F.X., Zheng D.H. and Wang K.H. Clinical analysis of 535 cases of chronic arsenic poisoning from coal burning. Chin. J. Med. 1992:31:560-562.
18. Liu J., Zheng B., Aposhian H.V., Zhou Y., Cheng M.L., Zhang A.H. and Waalkes M.P. Chronic arsenic poisoning from burning higharsenic- containing coal in Guizhou, China. Environ. Health Perspect. 2002:110: 119-122.
19. Mazumder D.N.G., Haque R., Gosh N., De B.K., Santra A., Chakraborty D. and Smith A.H. Arsenic levels in drinking water and the prevalence of skin lesions in West Bengal, India. Int. J. Epidemio. 1998:27: 871-877.
20. Meliker J.R., Wahl R.L., Cameron L.L. and Nriagu J.O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health. 2007: 2: 4-6.
21. Miltonprabu S. and Muthumani M. Silibinin ameliorates arsenic induced nephrotoxicity by abrogation of oxidative stress, inflammation and apoptosis in rats. Mol Biol Rep. 2012 DOI 10.1007/s11033-012-2029- 6.
22. Mumford J.L., Wu K., Xia Y., Kwok R., Yang Z., Foste J. and Sanders W.E. Jr. Chronic Arsenic Exposure and Cardiac Repolarization Abnormalities with QTInterval Prolongation in a Population-based Study. Environ. Health Perspect. 2007:115: 690-694.
23. Muthumani M. and Miltonprabu S. Silibinin potentially protects arsenic induced oxidative hepatic dysfunction in rats. Toxicol. Mech. Methods, 2012a:22: 277-288.
24. Muthumani M. and Miltonprabu S. Arsenic Induced Oxidative Stress and Its Possible Reversal by Chelation Therapy. A Journal of Toxicology. 2012b:2: 16-37.
25. Naso L.G., Ferrer E.G., Butenko N., Cavaco I., Lezama L., Rojo T., Etcheverry S.B. and Williams P.A.M. Antioxidant, DNA cleavage, and cellular effects of silibinin and a new oxovanadium(IV)/silibinin complex. J. Biol. Inorg. Chem. 2011:16:653-668.
26. North D.W., Gibb H.J. and Abernathy C.O. As: past, present and future considerations. In: Abernathy, C.O., Calderon, R.L., Chappell, W.R. (Eds.), As Exposure and Health Effects, London, Chapman and Hall 1997:407-423.
27. Parekh A.C. and Jung D.H. Cholesterol determination with ferric acetate-uranium acetate and sulfuric acid-ferrous sulphate reagents. Anal. Chem. 1970:42: 1423-1427.
28. Pietrangelo A., Borella F., Casalgrandi G., Montosi G., Ceccarelli D., Gallesi D., Giovannini F., Gasparetto A. and Masini A. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology. 1995:109:1941-1949.
29. Rajani G. and Purnima A. In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn. Indian J. Pharmacol. 2009:41: 227-232.
30. Rice E.W. Standard method of clinical chemistry. New York:Academic Press.1970.
31. Rossman T.G. Mechanism of arsenic carcinogenesis: An integrated approach. Mutat. Res. 2003:533: 37-66.
32. Rouser G., Fleischer S. and Yamamoto A. Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970:5: 494-496.
33. Saller R., Meier R. and Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001:61: 2035-2063.
34. Sillanaukee P. Laboratory markers of alcohol abuse. Alcohol. 1996:31: 613-616.
35. Singh R.P. and Agawal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid. Redox. Sign. 2002:4: 655-663.
36. Tapio S. and Grosche B. Arsenic in the aetiology of cancer. Mutat. Res. 2006:612:215-246.
37. Vijaya Padma V., Lalitha G., Shirony N.P. and Baskaran R. Effect of quercetin against lindane induced alterations in the serum and hepatic tissue lipids in wistar rats. Asian Pacific Journal of Tropical Biomedicine. 2012:910-915.
38. Wang C.H., Jeng J.S., Yip P.K., Chen C.L., Hsu L.I., Hsueh Y.M., Chiou H.Y., Wu M.M. and Chen C.J. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation. 2002:105: 1804-1809
39. Watson A.D. Thematic review series: Systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J. Lipid Res. 2006: 47: 2101-2111.
40. Wilson P., Abbott R. and Castelli W. High density lipoprotein cholesterol and mortality. The framingham heart study. Arteriosclerosis. 1988:8: 737-741.
41. Winterbourn C.C. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008: 4: 278-286.
42. Yih L., Peck K. and Lee T. Changes in gene expression profiles of human fibroblasts in response to sodium arsenite treatment. Carcinogenesis. 2002:23: 867-876.
43. Zhou Y.S., Du H., Cheng M.L., Liu J., Zhang X.J. and Xu L. The investigation of death from diseases caused by coal-burning type of arsenic poisoning. Chin. J. Endemiol. 2002:21: 484-486.